We specifically looked at therapies that target three key aspects in the life cycle of cancer cells: formation of the PACC state (with cyclin/CDK inhibitors), the stable PACC state (with metabolism modulation), and depolyploidization from the PACC state (with KIFC1 inhibitors). This evidence concerns the gene KIFC1 and cancer.